Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type KRAS, Wild type NRAS status confers therapeutic sensitivity to Cetuximab, Irinotecan in patients with Colorectal Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with irinotecan (14 days) for reimbursement as a treatment option for the second line treatment of adult patients with metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.
This statement is based on a regulatory approval from the Health Service Executive:
Second line therapy for metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy.